Home→Releases→Cardiovalve TR study reports results through three years
Releases

Cardiovalve TR study reports results through three years

At three years, 76.9% of patients in the TARGET Study had none or trace tricuspid regurgitation, according to results presented at PCR London Valves 2026. The trial also reported improvements in patients’ functional status and quality of life, alongside a favorable safety profile in a high-risk group.

Cardiovalve TR study reports results through three years

Venus Medtech (Hangzhou) Inc. said the multicenter, prospective, single-arm, open-label study enrolled 157 symptomatic patients with at least severe tricuspid regurgitation who were considered high risk for open-heart surgery. Of these, 148 received the Cardiovalve TR System. The mean age was 78; 71% were women, 99% had secondary tricuspid regurgitation and nearly 40% had torrential regurgitation. The study met its primary performance and safety endpoints, the company said. Prof. Georg Nickenig of the Heart Center at University Hospital Bonn presented the data on behalf of the investigators.

The primary performance endpoint—successful implantation with tricuspid regurgitation reduced to 2+ or less at 30 days—was met. Improvements in functional capacity and quality of life were maintained during follow-up: the mean six-minute walk test distance increased by 42 meters at one year, and the Kansas City Cardiomyopathy Questionnaire score rose by 20 points. At three years, 80% of patients were in New York Heart Association Class I or II, compared with 39.9% at baseline. Mean reductions in right-heart measurements at three years included 25% in inferior vena cava diameter, 22% in mid right ventricular end-diastolic diameter and 11% in basal right ventricular end-diastolic diameter.

The 30-day safety endpoint comprised major adverse events under the TVARC definition. At that point, all-cause mortality was 5.7%, heart-failure rehospitalization was 1.9%, and major access-site or vascular injury requiring surgical intervention was 5.1%. The company also reported lower rates with the Enhanced Delivery System than with the first-generation system: major bleeding was 5.0% versus 21%, and major vascular complications were 3.0% versus 8.8%.

Nickenig called the findings encouraging, citing the reduction in regurgitation and the safety profile, particularly with the newer device iteration. Venus Medtech said it is preparing for regulatory milestones and advancing its CE Mark application. Potential EU commercialization is expected in the second half of 2027.

Comments (0)

Leave a comment

No comments yet. Be the first!